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Abstract
To determine the frequency and the impact of parvovirus B19 (B19V) infection and its inﬂuence on the course of haematological and/or
oncological diseases in paediatric patients, consecutive serum and bone marrow samples from 110 were analyzed for markers of acute,
past and persistent B19V-infection using qPCR, ELISA and WesternLine. Twenty-seven out of 110 (24.5%) children suffered from non-
malignant diseases (anaemia, pancytopenia, autoimmune disorders); 68/110 (61.8%) patients had developed leukaemia, malignant lym-
phoma or solid malignant tumours; 15/110 patients (13.6%) presented with other symptoms. At admission, B19V-speciﬁc IgM and IgG
indicating acute or previous B19V-infection were observed in 5 (4.5%) and 48 patients (43.6%), respectively. B19V-DNA (103–109 geq/
mL) was detectable in serum and/or bone marrow of 22 patients (20.0%). These suffered from leukaemia (5), non-Hodgkin lymphoma
(2), solid tumours (6), autoimmune (4) and haematological (4) disease and fever (1). During clinical observation four further leukaemia
patients developed viraemia and persistent B19V-infection was observed in 13/22 DNA-positive patients. Treatment of B19V-DNA-posi-
tive cancer patients was associated with more supportive therapy involving erythrocyte and thrombocyte transfusion and/or antibiotic
therapy. Acute B19V-infection has been frequently observed in paediatric patients with haematological and/or oncological disease. In
patients with non-malignant diseases anaemia or autoimmune disorders were diagnosed in association with B19V-infection. Furthermore,
a signiﬁcant number of cancer patients displayed markers for acute, recent or persistent B19V-infection. This association may be
strengthened by frequent treatment with blood products combined with therapeutic immune suppression. In B19V-infected cancer
patients supportive therapy was more complex.
Keywords: Haematological disease, leukaemia, oncological disease, parvovirus B19, persistence
Original Submission: 25 February 2010; Revised Submission: 21 August 2010; Accepted: 22 August 2010
Editor: J.-M. Pawlotsky
Article published online: 3 September 2010
Clin Microbiol Infect 2011; 17: 1336–1342
10.1111/j.1469-0691.2010.03355.x
Corresponding author: S. Modrow, Institut fu¨r Medizinische
Mikrobiologie und Hygiene, Universita¨t Regensburg,
Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
E-mail: susanne.modrow@klinik.uni-regensburg.de
*Both authors contributed equally to this work.
Introduction
Parvovirus B19 (B19V) is the aetiological agent of erythema
infectiosum, a childhood rash disease, and of a wide spec-
trum of further diseases [1,2]. Due to the destruction of ery-
throid precursor cells in bone marrow, the main targets for
B19V replication, the patients develop anaemia, resulting in
haematopoietic disorders (e.g. transient red cell aplasia,
thrombocytopenia and pancytopenia in children and adults,
or hydrops fetalis in pregnant women) [3,4]. The patients
may develop acute polyarthropathy, arthritis and various
autoimmune disorders [5,6]; hepatitis, myocarditis, myositis,
vasculitis and encephalitis are observed rarely.
Acute B19V-infection is characterized by high viraemia and
the presence of viral genomes in the bone marrow. As par-
vovirus particles are extremely resistant to detergents and
environmental inﬂuences, both iatrogenic and nosocomial
transmission may occur, mainly by respiratory secretions but
also by blood and blood products. This presents a particular
risk for therapeutically immunosuppressed children with hae-
matological and/or malignant diseases, which may establish
persistent infection associated with long-lasting haematologi-
cal symptoms. Acute and persistent B19V-infection has been
shown to need enhanced supportive treatment and lead to
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complications in children with acute lymphoblastic leukaemia
(ALL) or Hodgkin-lymphoma, with the consequence of more
erythrocyte transfusions and extended hospitalization [7–10].
We determined the impact of B19V-infection on the dis-
ease course of 110 paediatric patients of a haemato-oncolog-
ical ward, hospitalized with haematological and oncological
disorders including solid malignant tumours. We analysed
consecutive serum and bone marrow samples for markers
indicating acute, past and persistent B19V-infection and cor-
related these data with the patient’s diseases and various
clinical parameters.
Material and Methods
Patients
Two hundred and ninety-one serum and 112 bone marrow
samples were obtained for diagnostic reasons from 110
Caucasian children and adolescents (age, 4–235 months; mean
age, 93.6 months) with haematological and/or oncological
diseases (65 males, 45 females). All were inpatients of a paedi-
atric hemato-oncological ward between December 2004 and
July 2007 (mean observation time, 12 months; range, 2–44
months, partially with intermission). Paired serum and bone
marrow samples were taken at the time of clinical admission
from enrolled patients. Some patients were included at the
time point of clinical therapy and stored serum and/or bone
marrow samples were analysed retrospectively. During treat-
ment follow-up samples were available from 60/110 patients
(54.5%). The clinical diagnosis was carried out according to
the actual guidelines for the respective diseases and encom-
passed a broad spectrum including various forms of leukaemia
(ALL, acute myeloid leukemia (AML), chronic myeloid
leukemia (CML), myelodysplastic syndrome (MDS)), malignant
lymphoma (morbus Hodgkin, non-Hodgkin lymphoma (NHL)),
solid malignant tumours (nephroblastoma, neuroblastoma,
rhabdomyosarcoma, brain tumours), and haematological
(anaemia, thrombocytopenia, pancytopenia, agranulocytosis,
thrombocytosis) and autoimmune disorders (Evan’s syndrome,
idiopathic thrombocytopenic purpura (ITP)).
According to diagnosis, patient subgroups A, B and C
were formed (Table 1). Patients (27/110, 24.5%) in group A
presented with non-malignant haematological diseases sub-
classiﬁed as autoimmune (14/110, 12.7%) and haematological
diseases (13/110, 11.8%). Group B patients (68/110, 61.8%)
were treated for malignancies and grouped into patients with
leukaemia (31/110, 28.2%), malignant lymphoma (12/110,
10.9%) and solid tumours (25/110, 22.7%). Group C
TABLE 1. Clinical course and serological markers for B19V-infection at the time of admission
Group of
patients/diagnoses
Age/months
(mean)
Patients IgG (%) IgM (%) Parvovirus B19 DNA (%)
Total
With
follow-up
VP1/VP2
parta
VP2
dena NS1 VP1/VP2
Total serum or
bone marrowb In Serum
In bone
marrow
Serum and
bone marrowc
Total 93.6 110 60 43.6 26.4 15.5 4.5 20.0 14.5 15.5 10.0
Group A (non-malignant) 89 27 8 40.7 33.3 22.2 7.4 29.6 18.5 29.6 18.5
Autoimmune disease 94 14 3 42.9 35.7 28.6 7.1 28.6 14.3 28.6 14.3
Evan’s syndrome 152 2 2 100.0 100.0 100.0 0 50.0 50.0 50.0 50.0
ITP 79 9 0 33.3 33.3 22.2 11.1 22.2 11.1 22.2 11.1
Other 131 3 1 33.3 0 0 0 33.3 0 33.3 0
Haematological disease 77 13 5 38.5 30.8 15.4 7.2 30.8 23.1 30.8 23.1
Fanconi anaemia 82 2 2 100.0 100.0 100.0 0 100.0 50.0 100 50.0
Anaemia 63 3 1 33.3 33.3 0 33.3 33.3 33.3 33.3 33.3
Thrombocytopenia 69 4 0 50.0 25.0 0 0 25.0 25.0 25.0 25.0
Pancytopenia 104 2 0 0 0 0 0 0 0 0 0
Agranulocytosis 16 1 1 0 0 0 0 0 0 0 0
Thrombocytosis 145 1 1 0 0 0 0 0 0 0 0
Group B (malignant disease) 101 68 50 45.6 26.5 14.7 4.4 19.1 14.7 11.8 7.4
Leukaemia 92 31 24 41.9 22.6 9.7 6.5 16.1 16.1 6.5 6.5
ALL 93 24 19 41.6 16.7 4.2 4.2 16.7 16.7 4.2 4.2
AML 84 3 3 33.3 66.7 33.3 33.3 0 0 0 0
CML 120 2 2 0 0 0 0 0 0 0 0
MDS 63 2 0 100.0 50.0 50.0 0 50.0 50.0 50.0 50.0
Malignant lymphoma 119 12 8 41.7 33.3 16.7 0 16.7 0 16.7 0
Hodgkin 132 3 3 33.3 66.7 33.3 0 0 0 0 0
Non-Hodgkin 113 9 5 44.4 22.2 11.1 0 22.2 0 22.2 0
Solid tumours 103 25 18 52.0 28.0 20.0 4.0 24.0 20.0 16.0 12.0
Neuroblastoma 62 6 5 50.0 16.7 0 0 16.7 0 16.7 0
Nephroblastoma 50 2 1 50.0 50.0 50.0 0 50.0 50.0 0 0
Rhabdomyosarcoma 131 3 2 100.0 33.3 33.3 33.3 66.7 66.7 66.7 66.7
Brain tumour 154 7 6 71.4 57.1 42.9 0 0 28.6 28.6 14.3 14.3
Other tumours 91 7 4 14.3 0 0 0 0 0 0 0
Group C (other diseases) 70 15 2 40.0 13.3 6.7 0 6.7 6.7 6.7 6.7
aPart, particulate antigen; den, denatured antigen.
bPatients with B19V-DNA present in either serum or bone marrow.
cPatients with B19V-DNA present in both serum and bone marrow.
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encompassed patients (15/110; 13.6%) mainly suffering from
unclear fever and abnormalities in blood counts, who were
hospitalized for diagnostic reasons (i.e. to exclude underlying
malignancies). With the exception of patients with solid
tumours (68.0% males), the female to male ratio was bal-
anced. Patients with follow-up samples were coded by Arabic
numbers (1,2,3) whereas Roman numbers (I, II, III) were
used for patients without follow-up samples.
Detection of B19V-speciﬁc antibodies and B19V-DNA
To determine seroprevalence, all sera were screened for
B19V-speciﬁc IgG and IgM against VP1-proteins (VP1-unique
region) and virus-like VP2-particles (VP1/VP2part) by ELISA
(RecomWell; Mikrogen GmbH, Neuried, Germany). IgG- and/
or IgM-positive sera were further analysed by WesternLine
(RecomLine; Mikrogen GmbH) for antibodies against virus-
like VP2-particles (VP2part), and denatured VP2- (VP2den),
VP1- (VP1-unique region and the aminoterminal VP1-region,
amino acids 1–499) and NS1-proteins. In general, IgG against
denatured VP2-proteins and epitopes is detectable together
with antibodies against VP2-particles in individuals with
recent B19V-infection having occurred up to 6 months
before testing [11–13]. NS1-speciﬁc IgG is frequently
observed several weeks following acute infection in cases
with prolonged viraemia or in patients who develop persis-
tent B19V-production [5,14,15].
DNA was isolated from 200 lL of each serum or bone
marrow sample using the QIAamp Blood kit (Qiagen, Hilden,
Germany). Each preparation (100 lL ﬁnal eluate) was used
immediately or stored at )20C. B19V-DNA was detected
in duplicate assays using the quantitative real-time TaqMan
PCR assay established for joint ampliﬁcation of B19V ge-
nomes, genotypes 1–3 [16]. Results were considered as posi-
tive if viral nucleic acids were detected in both assays. For
values indicative of low-level DNAemia (<1 · 103 geq/mL)
deﬁned numbers were not used due to test-speciﬁc devia-
tions. Further speciﬁcation of individual genotypes was not
performed.
Statistics
For statistical analysis, the chi-square test was applied to
compare proportions.
Results
With respect to all patients, a seroprevalence of 43.6% (48/
110) was observed at admission, as demonstrated by VP1/
VP2part-speciﬁc IgG (Table 1). In 22/110 (20%) children
B19V-DNA was detected in serum and/or bone marrow,
with B19V-speciﬁc IgM detectable in ﬁve of these patients,
conﬁrming acute infection. Twenty-nine out of 110 children
(26.4%) displayed IgG against VP2den, indicating recent
B19V-infection. NS1-speciﬁc IgG was observed in 17/110
(15.5%) children.
Patients with non-malignant diseases (group A)
Seroprevalence was 40.7% (11/27) in patients with non-malig-
nant diseases (Table 1). VP2den- and NS1-speciﬁc IgG was
detectable in 9/11 (81.8%) and 6/11 (54.4%) seropositive chil-
dren. On admission, B19V-DNA (102–103 to 7.6 · 106 geq/
mL) was present in serum and/or bone marrow of eight out
of eleven (72.2%) seropositive children (patients AI-AIV, A1–
A4) and three out of eight DNA-positive patients (A2–A4)
displayed B19V-genomes also in follow-up samples (Table 2).
Persistent viraemia was observed in patient A2 (Fanconi
anaemia) for 11 months. During the average observation of
21 months, none of the IgG-negative patients showed sero-
conversion or markers for acute B19V-infection.
Autoimmune disease. All seropositive patients (42.9%; 6/14)
displayed markers for acute and/or recent B19V-infection:
VP2den-speciﬁc IgG was present in combination with B19V-
DNA in bone marrow and/or serum samples of patients A1
(Evan’s syndrome), AI and AII (both ITP) and AIII (Kawasaki
disease); in patient AII, B19V-speciﬁc IgM was also detected
(Table 2).
Haematological disease. Five out of 13 patients (38.5%) dis-
played VP1/VP2part-speciﬁc IgG (Table 1). Four out of ﬁve
seropositive patients presented with acute B19V-infection
(Table 2). On admission, B19V-DNA was detectable in
serum and bone marrow of patients A2, A3 (both Fanconi
anaemia) and A4 (aplastic anaemia), and also during 6–
14 month follow-up periods. Initially, patient A4 was IgM-
positive, and B19V-DNA was present in peripheral blood
(1.2 · 105 geq mL) and bone marrow (7.6 · 106 geq/mL);
6 months later, the values decreased to 102–103 geq/mL
serum, indicating the gradual control of viraemia. A similar
situation was observed in patient A3 whereas patient A2 dis-
played low-levels of B19V-DNA in all available follow-up
samples, despite having B19V-speciﬁc antibodies (Table 2). In
combination with B19V-DNA in bone marrow, viraemia was
also observed as a marker for productive B19V-infection in
patient AIV presenting with thrombocytopenia.
Patients with malignant diseases (group B)
Seroprevalence was 45.6% (31/68 patients); in 18/68 (26.5%)
and 10/68 (14.7%) seropositive children, VP2den- and NS1-
speciﬁc IgG was detectable, respectively. At admission,
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B19V-DNA was present in serum and/or bone marrow of
13/68 (19.1%) patients, relating to 5/31 (16.1%) leukaemia
patients, 2/12 (16.6%) malignant lymphoma patients and 6/25
(24.0%) individuals with solid malignant tumours. During an
average observation of 10 months, B19V-DNA became
detectable in serum and/or bone marrow of four initially
DNA-negative patients (B2, B4, B5 and B7; Table 2).
Leukaemia. On admission, 13/31 (41.9%) children displayed
VP1/VP2part-speciﬁc IgG. Several patients displayed markers
for acute/recent or persistent infection. In MDS-patient BII
viraemia and VP2den-speciﬁc IgG were observed. Eight out
of 27 (29.6%) ALL/AML-patients (BI, B1–B7) displayed mark-
ers for productive B19V-infection, four of these (BI, B1, B3
and B6) presented with acute/recent B19V-infection at
admission and diagnosis of ALL; patients B1 and B6 were
unable to control B19V-infection during the following
months of chemotherapy. B19V-DNA became also
detectable in follow-up samples from ALL-patients B2, B4
and B5 and AML-patient B7 (Table 2). These children were
seropositive at admission, but B19V-DNA was not detectable
in serum or bone marrow. They developed viraemia during
treatment, and patient B2 established long-lasting virus per-
sistence. In bone marrow of AML-patient B7, B19V-DNA
was detected 32 days after initial diagnosis (Table 2).
Malignant lymphoma. At admission, 5/12 (41.6%) patients dis-
played VP1/VP2part-speciﬁc IgG; VP2den- and NS1-speciﬁc
TABLE 2. Serological and clinical parameters of B19V-DNA-positive patients without (AI–AIV, BI–BVIII and CI) and with fol-
low-up samples (A1–A4 and B1–B9)
Patient/sample number Disease
IgG IgM Viral DNA (geq/mL)
State of infectionDate (month/year) VP1/VP2 part VP2 den NS1 VP1/VP2 Serum Bone marrow
A1/1 Evan’s syndrome 04/2005 + + + ) 102–103 5.4 · 103 Acute/recent
A1/2 02/2006 + – ) ) – n.a. Past
A2/1 Fanconi anaemia 04/2005 + + + ) – 102–103 Acute/recent
A2/2 03/2006 + + + ) 102–103 102–103 Persistent
A3/1 Fanconi anaemia 11/2004 + + + ) 102–103 2.6 · 104 Acute/recent
A3/2 05/2005 + + ) – 2.3 · 103 Recent
A3/3 03/2006 + + ) – – Past
A4/1 Aplastic anaemia 08/2005 ) + ) + 1.2 · 105 7.6 · 106 Acute/recent
A4/2 02/2006 + + + ) 102–103 n.a. Persistent
AI ITP + + + ) – 102–103 Recent
AII ITP + + + +/) 1.4 · 103 4.1 · 104 Acute/recent
AIII Kawasaki disease n.a. n.a. n.a. n.a. n.a. 1.6 · 103 Unclear/recent?
AIV Thrombocytopenia + + ) + 1.9 · 103 3.4 · 103 Acute/recent
B1/1 ALL 08/2006 + ) ) ) 102–103 102–103 Recent
B1/2 09/2006 + + ) ) – 102–103 Recent
B1/3 06/2007 + + ) ) n.a. n.a. Past?
B2/1 ALL 10/2005 + ) ) ) – – Past
B2/2 10/2005 + + + ) 102–103 1.5 · 103 Persistent
B2/3 11/2005 + + + + 102–103 102–103 Persistent
B2/4 12/2005 + ) + ) – – Past
B2/5 01/2006 + + + ) – 102–103 Persistent
B2/6 02/2006 + + + ) 102–103 – Persistent
B3/1 ALL 01/2005 + ) ) ) 102–103 – Unclear/persistent?
B3/2 03/2006 + ) ) ) – – Past
B4/1 ALL 02/2005 + ) ) ) – – Past
B4/2 07/2005 + ) ) ) – 102–103 Persistent
B4/3 12/2005 + ) ) ) – – Past
B4/4 01/2006 + ) ) ) – Past
B5/1 ALL 04/2004 + ) ) ) – – Past
B5/2 09/2005 + ) ) ) – – Past
B5/3 10/2005 + + + + 102–103 102–103 Persistent
B5/4 12/2005 + ) ) ) – – Past
B5/5 03/2006 + ) ) ) – –
B6/1 ALL 12/2005 ) ) ) + 6.9 · 109 n.a. Acute
B6/2 03/2006 + + ) + 102–103 n.a. Persistent
B6/3 06/2006 + + + ) 1.2 · 104 n.a. Persistent
B7/1 AML 06/2006 ) + ) + – – Unclear
B7/2 07/2006 + + ) + – 102–103 Unclear/persistent?
B8/1 Rhabdomyo- 05/2005 + + + ) 102–103 102–103 Recent/persistent
B8/2 sarcoma 03/2006 + + + ) – n.a. Recent
B9/1 Brain tumour 05/2007 + + + ) 102–103 102–103 Recent/persistent
B9/2 06/2007 + + + ) 102–103 102–103 Recent/persistent
BI ALL + + ) ) 102–103 – Recent
BII MDS + + + ) 102–103 102–103 Recent
BIII NHL + + ) ) – 1.8 · 103 Unclear/recent?
BIV NHL + + ) ) – 102–103 Unclear/recent?
BV Neuroblastoma ) ) ) ) n.a. 102–103 Unclear
BVI Nephroblastoma + + + ) 2.1 · 103 n.a. Recent/persistent
BVII Rhabdomyosarcoma + + + ) 102–103 102–103 Recent/persistent
BVIII Brain tumour + + ) ) – 102–103 Recent
CI Fever + + ) ) 102–103 102–103 Recent
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IgG, respectively, were detectable in four and two of these
patients (Table 1). Viral DNA was not detected in any serum
sample, but in bone marrow of NHL-patients BIII and BIV (2/
12, 16.6%) B19V-DNA (Table 2).
Solid tumours. At admission, 13/25 (52.0%) patients were
seropositive. VP2den- and NS1-speciﬁc IgG was detectable in
seven and ﬁve of the seropositive patients, respectively
(Tables 1 and 2). In 6/25 (24%) patients (BV, neuroblastoma;
BVI, nephroblastoma; BVII, B8, rhabdomyosarcoma; BVIII, B9,
brain tumour) B19V-DNA was detected in sera and/or bone
marrow. The traceability of B19V-DNA did not change dur-
ing clinical observation of up to 8 months.
Patients with other diseases (group C)
Seroprevalence in patients presenting with neither non-malig-
nant haematological nor malignant diseases was 40.0% (6/15
patients; Table 1). In combination with IgG against VP2den,
B19V-DNA in serum and bone marrow of 1/15 patients
(patient CI) indicated recent infection (Table 2).
Inﬂuence of B19V-infection on the therapeutic regimen of
tumour patients
To study the inﬂuence of B19V-infection on clinical and ther-
apeutic management, we compared the treatment courses of
B19V-DNA-positive cancer patients (patients B1–B9) with
those of 11 B19-DNA-negative tumour patients. In general,
treatment was carried out in accordance with the respective
guidelines [17]. In the case of severe disease progression
individual treatment attempts were used. One death
occurred among the B19V-DNA-positive ALL-patients:
patient B5 died after 25.4 months of extensive therapy.
Whereas clinical relapses led to high-dose chemotherapy
with subsequent stem-cell transplantation in 33.3% of B19V-
DNA-positive patients, only one B19V-DNA-negative patient
(9.1%) showed this condition (Table 3). Regarding the dura-
tion and intensity of chemotherapy and treatment intervals
only minor differences were observed between B19V-DNA-
positive and negative tumour patients. This may be explained
by the small patient numbers in both groups.
Whereas most patients were treated with erythrocyte
and thrombocyte transfusions, the B19V-DNA-positive
patients required more donations of both cell preparations
than the B19V-DNA-negative patients. To compensate for
the difference in duration of therapy, the values were
adjusted to 100 days of treatment. B19V-DNA-positive trea-
ted patients required 3.4 (mean 48.9 mL/kg) erythrocyte and
3.1 thrombocyte transfusions; those numbers are in contrast
to 1.9 (25.9 mL/kg) erythrocyte and 0.8 thrombocyte dona-
tions per B19V-DNA-negative treated patient, respectively
(Table 3). Analysing the frequency (8.4 regular donations/
100 days/B19V-DNA-positive patient vs. 3.1 donations/
100 days/B19V-DNA-negative patient) and the duration (45.7
vs. 11.9 days, median) of antibiotic administration, similar
relations were observed. Seronegative and seropositive
patients without detectable amounts of B19V-DNA displayed
only minor differences.
Discussion
We analysed serum and bone marrow samples of children
with haematological and/or oncological disease for the pres-
ence of B19V-speciﬁc antibodies and viral DNA over a per-
iod of up to 44 months. On admission, an overall
seroprevalence of 43.6% was observed, that was lowest in
children with non-malignant haematological diseases (38.5%;
mean age: 76.8 months) and highest in malignant lymphoma
patients (52%; mean age, 119 months). This is in accordance
with age-matched healthy European children [18,19].
Only one of six seropositive patients (16.7%) with neither
haematological nor oncological disorders (group C) displayed
low-level viraemia. Similar values for viraemia have been
detected in healthy children and paediatric patients with
TABLE 3. Details used for treatment of B19V-DNA-positive and negative leukaemia patients
Therapeutic details
Patients
Erythrocytes Thrombocytes Treatment with antibioticsa
Patients with
HDC+SCT
Patients
treated
Donations/
patientb
Patients
treated
Donations/
patientb
Patients
treated
Donations/
patientb treated
Duration/patient
treated (days)
B19V-DNA negative 1/11
(9.1%)
10/11
(90.9%)
1.9
25.9 mL/kg bw
10/11
(90.9%)
0.8 10/11
(90.9%)
3.1 11.9
B19V-DNA positive 3/9
(33.3%)
7/9
(77.7%)
3.4
48.9 mL/kg bw
5/9
(55.6%)
3.1 7/9
(77.7%)
8.4 45.7
Bw, body weight; HDC + SCT, high dose chemotherapy + stem cell transplantation.
aOne donation of antibiotic = the dose of each compound that has been applied according to the recommendation per day.
bMean numbers of donations of erythrocyte/thrombocyte concentrates per 100 days or donations of antibiotics per treated patient per 100 days.
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non-infectious disorders and reﬂect the incidence of
B19V-infection in children [5,20]. This is, however, in
contrast to haematological (group A, 8/11 patients, 72.2%)
and oncological patients (group B, 17/31 patients, 54.8%),
who displayed signiﬁcantly higher values for DNA prevalence
in seropositive patients (p <0.001).
Due to the destruction of erythroid precursors during
acute infection, patients with underlying haematological dis-
eases are at risk of developing severe anaemia, transient
aplastic crisis and reticulocytopenia. As a consequence, B19V-
DNA was detected most frequently in children with non-
malignant haematological diseases. In context with acute
B19V-infection, Fanconi anaemia became apparent in patients
A2 and A3 and patient A4 developed clinically apparent aplas-
tic anaemia without an underlying condition. Furthermore,
B19V-infection is known to cause thrombocytopenia and to
trigger autoimmune disorders [5,20–24]. We observed mark-
ers for acute or recent B19V-infection in ﬁve patients pre-
senting with autoimmune disease: ITP was diagnosed in
patients AI and AII, Kawasaki-disease in patient AIII, thrombo-
cytopenia in patient AIV and Evan’s syndrome in patient A1,
even though, contraversially, Kawasaki-disease and Evan’s syn-
drome have been associated with B19V-infection [25–27].
Following acute B19V-infection transient neutropenia and
pancytopenia may be established and the reduced immune
control may be responsible for the appearance of underly-
ing malignant diseases [1,2]. Furthermore B19V-replication
leads to the destruction of erythroid precursors followed
by a massive proliferation of reticulocytes in bone marrow
[1]. Also this situation may affect the division of residual
tumour cells and explain the frequent detection of B19V-
DNA in 13/68 patients (19.1%) with malignancies at the
time of admission. B19V-DNA was detectable in six
patients with solid tumours. In patient B5 (a child success-
fully treated previously) acute B19V-infection was associated
with an ALL-relapse. As acute B19V-infection has been
described to precede ALL [28–31], it may be assumed that
it also triggered this ALL-relapse. Combined with markers
for previous B19V infection, ALL-patients B1, B3 and BI dis-
played low-level viraemia. Erythrocyte transfusions had been
applied to patient B1 1 day, and to patient B3 3 months,
prior to hospital admission and serum acquisition in the
present study. As back-up samples were not available, it is
unclear whether B19V was acquired via natural infection or
transfusion. Alternatively, recent infection or reactivation of
latent B19V-DNA may be responsible for this ﬁnding. In
ALL/AML-patients B2, B4, B5 and B7, B19V-DNA was ﬁrst
observed during maintenance chemotherapy. All four
patients were treated with erythrocyte and/or thrombocyte
transfusions combined with additional blood products (albu-
min, IVIG). As B19V is a frequent contaminant of blood
and blood products this ﬁnding raises the suspicion of iat-
rogenic transmission.
In B19V-DNA-positive cancer patients, courses of neo-
plastic disease were more severe and associated with higher
number of relapses. The therapeutic supportive regimen
required more erythrocyte and thrombocyte transfusions
(Table 3). Neutropenia and lymphocytosis combined with
reduced haemoglobin levels and red blood cell counts in
B19V-DNA-positive paediatric leukaemia patients have been
also described by Zaki and co-workers [32,33]. Recent publi-
cations report that B19V-DNA-positive ALL-patients
required more blood transfusions than B19V-DNA-negative
ALL-patients [8,10,27]. As our study included patients with
malignant lymphoma and solid tumours we could show that
the necessity for enhanced administration of blood cells and
of antibiotics over extended periods is not only observed
with leukaemia.
B19V-infection was shown to be an important cause of
anaemia and cytopenia in children with haematological and/
or oncological diseases. In patients with unexplained cytope-
nia, B19V-infection should be considered and diagnostically
conﬁrmed. In B19V-DNA-positive leukaemia and solid
tumour patients, treatment was associated with complica-
tions that required more blood transfusions and courses of
antibiotics. Frequent blood transfusions are not only associ-
ated with high costs, however, but also involve the additional
risk of transferring infections. Due to these problems mea-
sures to avoid iatrogenic or nosocomial B19V transmission
have to be undertaken.
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